in this issue
Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients
Alembic Completes Acquisition of Dabur Pharma
1:31 PM MDT | July 24, 2007 | DR
Pharmaceutical company Alembic (Vadodara, India) says it has completed the acquisition of the non-oncology formulation business of Dabur Pharma (New Delhi) for approximately $37 million. Alembic acquired full rights to market 24 Dabur brands, under the terms of the deal. Most of the brands are in the high-growth lifestyle therapeutic segments of cardiology, diabetology, and gynecology. Alembic is the largest player in the anti-infective drug segment in India, and aims to increase market share in the lifestyle segment. “With this acquisition, we have a ready...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee